CA2680842C - N-acetyl mannosamine ou derives de celui-ci pour le traitement d'une maladie renale chez un mammifere - Google Patents
N-acetyl mannosamine ou derives de celui-ci pour le traitement d'une maladie renale chez un mammifere Download PDFInfo
- Publication number
- CA2680842C CA2680842C CA2680842A CA2680842A CA2680842C CA 2680842 C CA2680842 C CA 2680842C CA 2680842 A CA2680842 A CA 2680842A CA 2680842 A CA2680842 A CA 2680842A CA 2680842 C CA2680842 C CA 2680842C
- Authority
- CA
- Canada
- Prior art keywords
- acetyl mannosamine
- derivative
- leu
- val
- gly
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
L'invention concerne des compositions et des procédés pour traiter le dysfonctionnement d'un rein et d'un muscle qui comprennent l'utilisation de quantités thérapeutiques de mannosamine de N-acétyle.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2903133A CA2903133C (fr) | 2007-05-31 | 2008-05-30 | N-acetyl mannosamine ou derives de celui-ci pour le traitement d'une maladie renale chez un mammifere |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93245107P | 2007-05-31 | 2007-05-31 | |
US60/932,451 | 2007-05-31 | ||
PCT/US2008/006895 WO2008150477A2 (fr) | 2007-05-31 | 2008-05-30 | Mannosamine de n-acétyle en tant qu'agent thérapeutique |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2903133A Division CA2903133C (fr) | 2007-05-31 | 2008-05-30 | N-acetyl mannosamine ou derives de celui-ci pour le traitement d'une maladie renale chez un mammifere |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2680842A1 CA2680842A1 (fr) | 2008-12-11 |
CA2680842C true CA2680842C (fr) | 2015-11-24 |
Family
ID=39952249
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2680842A Active CA2680842C (fr) | 2007-05-31 | 2008-05-30 | N-acetyl mannosamine ou derives de celui-ci pour le traitement d'une maladie renale chez un mammifere |
CA2903133A Active CA2903133C (fr) | 2007-05-31 | 2008-05-30 | N-acetyl mannosamine ou derives de celui-ci pour le traitement d'une maladie renale chez un mammifere |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2903133A Active CA2903133C (fr) | 2007-05-31 | 2008-05-30 | N-acetyl mannosamine ou derives de celui-ci pour le traitement d'une maladie renale chez un mammifere |
Country Status (6)
Country | Link |
---|---|
US (5) | US8410063B2 (fr) |
EP (3) | EP2155207A2 (fr) |
JP (4) | JP2010529021A (fr) |
CA (2) | CA2680842C (fr) |
IL (3) | IL268475B (fr) |
WO (1) | WO2008150477A2 (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008150477A2 (fr) | 2007-05-31 | 2008-12-11 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Mannosamine de n-acétyle en tant qu'agent thérapeutique |
US9018174B2 (en) * | 2008-05-28 | 2015-04-28 | Hibm Research Group, Inc. | Mouse model and treatment of hereditary inclusion body myopathy |
GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
US8987232B2 (en) | 2008-09-04 | 2015-03-24 | The University Of Tokyo | Agent for ameliorating brain hypofunction |
JP5557243B2 (ja) * | 2010-02-26 | 2014-07-23 | 国立大学法人 東京大学 | 睡眠の改善剤 |
US9241896B2 (en) | 2008-12-19 | 2016-01-26 | Ultragenyx Pharmaceutical Inc. | Methods and formulations for treating sialic acid deficiencies |
JP5626734B2 (ja) * | 2009-05-15 | 2014-11-19 | 公益財団法人ヒューマンサイエンス振興財団 | Gneタンパク質の機能低下に起因する疾患の治療用医薬剤、食品組成物 |
UA110325C2 (en) * | 2009-07-03 | 2015-12-25 | Australian Biomedical Company Pty Ltd | Medicinal carbohydrates for treating respiratory conditions |
MX2012010533A (es) * | 2010-03-12 | 2013-02-11 | Dsm Ip Assets Bv | Suplementacion materna de acido sialico. |
US20110301103A1 (en) * | 2010-06-05 | 2011-12-08 | Chugh Sumant S | Methods of Treatment |
US9139629B2 (en) | 2010-06-05 | 2015-09-22 | The Uab Research Foundation | Methods for treatment of nephrotic syndrome and related conditions |
DK2575858T3 (en) * | 2010-06-05 | 2018-03-12 | Sumant S Chugh | METHOD OF TREATING NEPHROTIC SYNDROME AND RELATED DISEASES |
US9511015B2 (en) | 2010-07-13 | 2016-12-06 | Ultragenyx Pharmaceutical Inc. | Methods and formulations for treating sialic acid deficiencies |
WO2012082830A1 (fr) * | 2010-12-14 | 2012-06-21 | Hibm Research Group, Inc. | Biomarqueurs du sérum pour hibm |
EP2704597B1 (fr) * | 2011-05-05 | 2021-04-07 | Life Science Nutrition AS | Compositions améliorant l'efficacité, et procédés d'utilisation |
US20130058998A1 (en) * | 2011-09-07 | 2013-03-07 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Encapsulated n-acetylmannosamine or n-acetylneuraminic acid to increase sialylation |
US8840926B2 (en) | 2011-10-24 | 2014-09-23 | Ultragenyx Pharmaceutical Inc. | Sialic acid analogs |
WO2013109906A2 (fr) * | 2012-01-18 | 2013-07-25 | Ultragenyx Pharmaceutical Inc. | Procédés et formulations permettant de traiter les déficiences en acide sialique |
US20160025717A1 (en) | 2013-03-14 | 2016-01-28 | Emory University | Hyposialylation disorders |
AU2013408774B2 (en) * | 2013-12-27 | 2017-06-29 | Colgate-Palmolive Company | Prebiotic oral care methods using a saccharide |
US10493087B2 (en) | 2015-02-25 | 2019-12-03 | The United States of America, as represented by National Institute of Health | Sialylation-increasing therapies for diseases associated with oxidative stress |
TW201720803A (zh) | 2015-09-14 | 2017-06-16 | 超基因克斯製藥公司 | 唾液酸或其鹽或溶劑合物之晶型 |
WO2017188692A1 (fr) * | 2016-04-25 | 2017-11-02 | 경북대학교 산학협력단 | Composition antimicrobienne contenant de l'acide 7,10- époxyoctadéca-7,9-diénoïque comme ingrédient actif |
KR101792239B1 (ko) | 2016-11-01 | 2017-10-31 | 경북대학교 산학협력단 | 7,10-에폭시옥타데카-7,9-다이에노산 및 항생제를 유효성분으로 포함하는 항균 조성물 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4051842A (en) | 1975-09-15 | 1977-10-04 | International Medical Corporation | Electrode and interfacing pad for electrical physiological systems |
DE2626348C3 (de) | 1976-06-11 | 1980-01-31 | Siemens Ag, 1000 Berlin Und 8000 Muenchen | Implantierbare Dosiereinrichtung |
US4383529A (en) | 1980-11-03 | 1983-05-17 | Wescor, Inc. | Iontophoretic electrode device, method and gel insert |
US4610868A (en) * | 1984-03-20 | 1986-09-09 | The Liposome Company, Inc. | Lipid matrix carriers for use in drug delivery systems |
US4962091A (en) | 1986-05-23 | 1990-10-09 | Syntex (U.S.A.) Inc. | Controlled release of macromolecular polypeptides |
DE3935906A1 (de) * | 1989-10-27 | 1991-05-02 | Reutter Werner | Verwendung von galaktose zur (par)enteralen ernaehrung und versorgung in der intensivmedizin sowie hierzu geeignete praeparationen |
WO1994007529A1 (fr) | 1992-09-25 | 1994-04-14 | Neorx Corporation | Inhibiteur therapeutique de cellules des muscles vasculaires lisses |
CA2155910C (fr) * | 1995-08-11 | 1999-12-14 | George Wu | Solution aqueuse biocompatible pour utilisation en dialyse peritoneale ambulatoire continue |
US6274568B1 (en) * | 1998-08-06 | 2001-08-14 | Ronald L. Schnaar | Compounds for altering cell surface sialic acids and methods of use therefor |
CA2442146A1 (fr) | 2001-03-29 | 2002-10-10 | The Scripps Research Institute | Formulations comprenant des ingredients actifs pieges et utilisations de ces formulations |
WO2003028709A2 (fr) * | 2001-09-26 | 2003-04-10 | Werner Reutter | Utilisation de devrives de mannosamine pour la stimulation de la croissance des neurites |
WO2003097073A1 (fr) * | 2002-04-19 | 2003-11-27 | Astion Development A/S | Combinaison d'agonistes de recepteur adrenergique beta-2 et d'un sucre amine et leur utilisation pour le traitement de troubles immunomodulateurs |
WO2004068970A2 (fr) | 2003-01-31 | 2004-08-19 | The Procter & Gamble Company | Moyen pour ameliorer l'aspect de tissus keratiniques de mammiferes |
US9315532B2 (en) * | 2005-05-24 | 2016-04-19 | The Johns Hopkins University | Fatty acid carbohydrate hybrid molecules as therapeutic agents and methods thereof |
WO2008150477A2 (fr) | 2007-05-31 | 2008-12-11 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services National Institutes Of Health | Mannosamine de n-acétyle en tant qu'agent thérapeutique |
JP5626734B2 (ja) | 2009-05-15 | 2014-11-19 | 公益財団法人ヒューマンサイエンス振興財団 | Gneタンパク質の機能低下に起因する疾患の治療用医薬剤、食品組成物 |
US20110301103A1 (en) * | 2010-06-05 | 2011-12-08 | Chugh Sumant S | Methods of Treatment |
US20160025717A1 (en) | 2013-03-14 | 2016-01-28 | Emory University | Hyposialylation disorders |
-
2008
- 2008-05-30 WO PCT/US2008/006895 patent/WO2008150477A2/fr active Application Filing
- 2008-05-30 EP EP08767999A patent/EP2155207A2/fr not_active Withdrawn
- 2008-05-30 CA CA2680842A patent/CA2680842C/fr active Active
- 2008-05-30 CA CA2903133A patent/CA2903133C/fr active Active
- 2008-05-30 US US12/530,433 patent/US8410063B2/en active Active
- 2008-05-30 EP EP16196935.7A patent/EP3175859B1/fr active Active
- 2008-05-30 EP EP20197500.0A patent/EP3799874A1/fr active Pending
- 2008-05-30 JP JP2010510363A patent/JP2010529021A/ja active Pending
- 2008-05-30 IL IL268475A patent/IL268475B/en unknown
-
2009
- 2009-09-10 IL IL200872A patent/IL200872A/en active IP Right Grant
-
2013
- 2013-03-08 US US13/791,576 patent/US9095597B2/en active Active
-
2014
- 2014-10-10 JP JP2014208695A patent/JP6283298B2/ja active Active
-
2015
- 2015-06-29 US US14/754,304 patent/US20150290229A1/en not_active Abandoned
-
2016
- 2016-04-10 IL IL245026A patent/IL245026B/en active IP Right Grant
- 2016-08-15 JP JP2016159061A patent/JP2016196505A/ja active Pending
-
2017
- 2017-09-12 US US15/702,529 patent/US10335426B2/en active Active
-
2018
- 2018-08-24 JP JP2018156853A patent/JP6694026B2/ja active Active
-
2019
- 2019-05-20 US US16/417,488 patent/US10953026B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20130196936A1 (en) | 2013-08-01 |
EP3799874A1 (fr) | 2021-04-07 |
EP3175859B1 (fr) | 2020-09-23 |
IL268475B (en) | 2022-08-01 |
IL200872A0 (en) | 2010-05-17 |
JP2015042653A (ja) | 2015-03-05 |
US8410063B2 (en) | 2013-04-02 |
IL268475A (en) | 2019-09-26 |
IL245026B (en) | 2019-08-29 |
JP6283298B2 (ja) | 2018-02-21 |
US20180117072A1 (en) | 2018-05-03 |
JP2016196505A (ja) | 2016-11-24 |
IL200872A (en) | 2016-04-21 |
JP6694026B2 (ja) | 2020-05-13 |
WO2008150477A3 (fr) | 2009-11-26 |
US20150290229A1 (en) | 2015-10-15 |
WO2008150477A2 (fr) | 2008-12-11 |
CA2903133C (fr) | 2021-10-19 |
US10335426B2 (en) | 2019-07-02 |
JP2018184475A (ja) | 2018-11-22 |
CA2903133A1 (fr) | 2008-12-11 |
CA2680842A1 (fr) | 2008-12-11 |
IL245026A0 (en) | 2016-05-31 |
JP2010529021A (ja) | 2010-08-26 |
EP2155207A2 (fr) | 2010-02-24 |
US20190374561A1 (en) | 2019-12-12 |
US20100249047A1 (en) | 2010-09-30 |
EP3175859A1 (fr) | 2017-06-07 |
US10953026B2 (en) | 2021-03-23 |
US9095597B2 (en) | 2015-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10953026B2 (en) | N-acetyl mannosammine as a therapeutic agent | |
Wang et al. | The role and potential of sialic acid in human nutrition | |
Basta et al. | Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses | |
Xu et al. | Safety, pharmacokinetics and sialic acid production after oral administration of N-acetylmannosamine (ManNAc) to subjects with GNE myopathy | |
JP4633939B2 (ja) | 治療におけるグルコシルセラミド合成阻害剤と糖脂質分解酵素の組み合わせ | |
RU2731616C2 (ru) | Ферментная заместительная терапия с увеличением дозы для лечения недостаточности кислой сфингомиелиназы | |
Reece et al. | Dietary intake of myo-inositol and neural tube defects in offspring of diabetic rats | |
Selim et al. | Pancreatic response to gold nanoparticles includes decrease of oxidative stress and inflammation in autistic diabetic model | |
Yu et al. | D-ribose is elevated in T1DM patients and can be involved in the onset of encephalopathy | |
Prieto | Profiles of human milk oligosaccharides and production of some human milk oligosaccharides in transgenic animals | |
Freeze | Towards a therapy for phosphomannomutase 2 deficiency, the defect in CDG-Ia patients | |
Sadowska-Woda et al. | Nutritional supplement attenuates selected oxidative stress markers in pediatric patients with cystic fibrosis | |
Li et al. | GM2/GD2 and GM3 gangliosides have no effect on cellular cholesterol pools or turnover in normal or NPC1 mice | |
Derks et al. | Disorders of carbohydrate absorption, transmembrane transport and metabolism | |
Oparinde et al. | Effect of Moringa oleifera leaf extract on serum lipids and glycaemic control in alloxan induced diabetic albino rats | |
Kuske | Plasma glycosphingolipids in lipid disorders | |
Klein et al. | Comparison of methods for prediction of nephrotoxicity during development | |
MITRA | THE BIOCHEMICAL & PHYSIOLOGICAL IMPLICATION OF GOUT | |
Salter et al. | Influence of maternal nutrition on the metabolic syndrome and cardiovascular risk in the offspring | |
Castejón Vega | Autophagy dysfunctions and lysosomal permeabilization in Tay-Sachs and Sandhoff diseases | |
Thomas et al. | Lysosomal Storage, Peroxisomal, and Glycosylation Disorders and Smith–Lemli–Opitz Syndrome Presenting in the Neonate | |
EP3053575B1 (fr) | Agent servant à prévenir ou améliorer un dysfonctionnement rénal | |
Zhang et al. | 10 Pharmacogenomics and Alternative Medicine | |
Obeid et al. | Advances and controversies in B‑Vitamins and choline |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20130530 |